Chardan raised the firm’s price target on 4D Molecular to $39 from $38 and keeps a Buy rating on the shares after the company held a wet age-related macular degeneration development day. The firm says the updated 4D-150 safety and activity profile remain consistent with prior readouts. The 4FRONT-1 Phase III trial will enroll recently-diagnosed treatment-naive wet AMD patients, with a design intended to be largely consistent with other Phase III trials in this population and to maximize chances of hitting the primary endpoint, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- 4D Molecular announces data from PRISM, 4FRONT trials
- 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
- JMP Securities healthcare analysts hold an analyst/industry conference call
- 4DMT to Participate in the 2024 Cantor Global Healthcare Conference
- 4D Molecular to host 4D-150 Wet AMD Development Day